Skip to main content

Table 5 2TCM and SRTM-derived BPND of [18F]FEt-AMC13 per brain region in control and raclopride-treated rats

From: Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers

Region of interest 2TCM BPND (V T-based) SRTM BPND
Control Raclopride Control Raclopride
Striatum 0.56 ± 0.05 0.41 ± 0.05 (−27%)* 0.51 ± 0.02 0.38 ± 0.05 (−26%)**
Hippocampus 0.30 ± 0.07 0.26 ± 0.06 (−13%) 0.26 ± 0.04 0.23 ± 0.05 (−13%)
Thalamus 0.33 ± 0.02 0.30 ± 0.01 (−10%)* 0.28 ± 0.06 0.26 ± 0.02 (−7%)
Hypothalamus 0.22 ± 0.03 0.18 ± 0.06 (−19%) 0.21 ± 0.03 0.16 ± 0.04 (−23%)
Cortex 0.13 ± 0.04 0.10 ± 0.02 (−27%) 0.11 ± 0.03 0.08 ± 0.02 (−24%)
Brainstem 0.22 ± 0.02 0.10 ± 0.02 (−53%)** 0.18 ± 0.04 0.07 ± 0.03 (−60%)**
Olfactory bulbs 0.08 ± 0.13 0.01 ± 0.04 (−88%) 0.10 ± 0.13 0.11 ± 0.05 (+10%)
Pituitary 0.36 ± 0.07 0.13 ± 0.04 (−23%) 0.71 ± 0.32 0.55 ± 0.53 (−22%)
  1. Data are presented as means ± SD, n = 4 for the control group and n = 3 for the raclopride-treated group (except for the SRTM BPND values, where n = 4). Next to the BPND values of the raclopride-treated group, percentage of change relative to the control group is shown
  2. *p < 0.05; **p < 0.01, 2-sided Welch test